Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Stēto logo — Creating continuous care in diabetes

Stēto

Creating continuous care in diabetes

Founded 2022 France France 12 employees Seed Total: $1.20M Health Care, Health and Wellness

General Information

Company Name Stēto
Founded Year 2022
Location France France
Employees 12
Industries Health Care, Health and Wellness
Funding Stage Seed
Business Model B2B2C, Platform, B2B
Revenue Model Service Fee, Subscription, Commission
Social

BounceWatch is an independent company data service, not affiliated with Stēto. To contact Stēto, visit steto.care.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Stēto compare?

A PDF of Stēto and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Stēto soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Stēto

Stēto, founded in 2022 and headquartered in France, is poised to revolutionize diabetes care with its innovative Remote Patient Monitoring solutions. The company operates in the Health Care and Health and Wellness industries, addressing the urgent global need for adaptive diabetes management. With an alarming projection of 800 million people affected by diabetes by 2045, traditional healthcare models are proving inadequate.

The company's slogan, "Creating continuous care in diabetes", encapsulates its mission to transform diabetes treatment beyond periodic medical appointments. By leveraging digital tools, Stēto aims to deliver daily medical support, cultivating a proactive approach to diabetes management.

Recently, Stēto secured a €1.20M Seed Round investment on 10 November 2023, with backing from the reputable Bpifrance. This funding underscores investor confidence in Stēto's potential to lead significant advancements in diabetes care.

Business keywords: Remote Patient Monitoring, Diabetes Management, Digital Health Solutions, Chronic Disease Management, Healthcare Innovation, Digital Therapeutics, Patient Support, Medical Technology, Healthcare Software, Telehealth, Continuous Care Models, Patient Engagement, Preventive Care

Services & Products

Telemonitoring platform for diabetes
Collaboration between endocrinologists and specialized nurses
Continuous patient education and support
Integration with insulin therapy devices

Target Customers

Endocrinologists Diabetes specialists Patients with diabetes (Type 1, Type 2, Gestational) Nurses specializing in diabetology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round €1.20M 1
Bpifrance
Bpifrance
10 Nov 2023
Non Equity Assistance Undisclosed 1
AGORANOV
AGORANOV
01 Oct 2023

Stēto Alternatives & Competitors

View All Alternatives
Stēto vs
Clear.bio
Clear.bio The Netherlands

“We want to help billions of people with type 2 diabetes to become the best and healthiest version o...

Venture round
14 employees
AI, Health Care
Stēto vs
Craniometrix
Craniometrix United States

The all-in-one dementia care (GUIDE) solution for medical practices and families, leveraging the pow...

Seed
26 employees
Health Care, Health and Wellness
Stēto vs
DEARhealth
DEARhealth The Netherlands

DEARhealth biedt dynamische en risicogebaseerde zorgpaden en slimme beslissingsondersteuning voor me...

Acquired
9 employees
Health Care, Health and Wellness
Also compare with: Stēto vs Orpyx® Orpyx® View all alternatives

FAQ About Stēto

Creating continuous care in diabetes
Stēto was founded in 2022.
Stēto is headquartered in France.
Stēto operates in Health Care and Health and Wellness. Its work centres on Remote Patient Monitoring, Diabetes Management, Digital Health Solutions and Chronic Disease Management. Its customers include Endocrinologists, Diabetes specialists and Patients with diabetes (Type 1, Type 2, Gestational).
Stēto has a B2B2C, Platform and B2B business model. Its revenue comes from Service Fee, Subscription and Commission.
Stēto has approximately 12 employees.
Stēto has completed 2 funding rounds, raising a total of $1.20M. The latest funding stage is Seed.
Stēto offers: Telemonitoring platform for diabetes, Collaboration between endocrinologists and specialized nurses, Continuous patient education and support, Integration with insulin therapy devices.
Top alternatives and competitors to Stēto include Clear.bio, Craniometrix, DEARhealth, Noctrix Health, Inc., Aktiia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stēto and Clear.bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Stēto, https://bouncewatch.com/company/steto-1, updated 24 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes